Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
microbiome
Biotech
MaaT's phase 3 GvHD trial hits goal, teeing up microbiome filing
The phase 3 graft-versus-host disease trial hit its primary endpoint, positioning MaaT to seek approval of the microbiome therapy in mid-2025.
Nick Paul Taylor
Jan 9, 2025 5:18am
Xeno's gastric-bypass pill alternative to be tested for C. diff
Jan 6, 2025 7:15am
Compounds from vaginal bacteria show promise for inflammation
Oct 17, 2024 11:00am
Florey launches with plan to keep our guts in check
Oct 1, 2024 7:00am
Crestone’s antibiotic beats vancomycin at treating C. diff
Sep 5, 2024 3:11pm
Viral protein suppresses graft vs. host disease in mice
Jul 19, 2024 5:30am